Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints
Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)
Men must agree to use a reliable method of birth control or remain abstinent during the study
Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs)
Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due to either an inadequate response (based on a minimum of 12 weeks on therapy) or documented intolerance.
You may not be if
Current use of biologic agents for treatment of Ps or PsA
Inadequate response to greater than 2 biologic DMARDs
Current use of more than one cDMARDs
Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy
Serious disorder or illness other than psoriatic arthritis
